Aditxt to Participate in the 2022 Virtual Growth Conference

Rhea-AI Summary

Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company, announced that CEO & Co-Founder Amro Albanna will present at the 2022 Virtual Growth Conference, hosted by Maxim Group LLC and M-Vest from March 28th - 30th between 9:00 a.m. - 5:00 p.m. EDT. This conference will cover various sectors, including biotech and healthcare, featuring presentations, discussions, and Q&As with executives. Aditxt focuses on mapping and reprogramming the immune system, aiming to address organ rejection and autoimmune diseases.

Presented by Maxim Group LLC and Hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT

RICHMOND, Va.--(BUSINESS WIRE)-- Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company developing technologies focused on mapping and reprogramming the immune system, announced today that Company CEO & Co-Founder, Amro Albanna, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.

https://m-vest.com/events/2022-virtual-growth-conference/p/adtx

Sign up here to access the presentation

During this virtual conference, investors will hear from executives from a wide range of sectors including Biotech, Clean Energy, Electric Vehicles, Financial Services, Fintech & REITS, Gaming & Entertainment, Healthcare, Healthcare IT, Infrastructure, Shipping and Technology/ Media/Telecom. The conference will feature company presentations, fireside chats, roundtable discussions, and live Q&A with CEOs moderated by Maxim Research Analysts.

This conference will be live on M-Vest. To attend, just sign up to become an M-Vest member.

Click Here to Reserve your seat

About Aditxt

Aditxt is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. Aditxt’s immune mapping technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

For more information, please visit: www.aditxt.com and www.AditxtScore.com

Forward-looking statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made. The Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005352/en/

Media and investor relations contact

Aditxt Investor Communications

ir@aditxt.com

www.aditxt.com

Source: Aditxt, Inc.

FAQ

When will Aditxt present at the Virtual Growth Conference?

Aditxt will present at the Virtual Growth Conference from March 28th to 30th, 2022.

Who is the CEO of Aditxt presenting at the conference?

The CEO of Aditxt presenting at the conference is Amro Albanna.

What is the focus of Aditxt's technologies?

Aditxt focuses on mapping and reprogramming the immune system for medical applications.

How can I attend the Virtual Growth Conference featuring Aditxt?

You can attend the Virtual Growth Conference by signing up to become an M-Vest member.

What sectors are covered in the Virtual Growth Conference?

The conference covers sectors including Biotech, Clean Energy, Financial Services, and Healthcare.